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Sumamry Anti-peptic and anti-inflammatory actions of ecabet sodium might be beneficial in
either improving gastritis or relieving dyspeptic symptoms. This study was designed to evaluate
the clinical efficacy of ecabet sodium on dyspeptic symptoms and to elucidate the molecular
mechanism attributable to symptom relief in patients with chronic gastritis. Two hundred and
sixty eight chronic gastritis patients with persistent dyspepsia received ecabet sodium 1 g b.i.d.
for 2 weeks, after which dyspeptic symptoms were reassessed with a questionnaires as before.
The changes of interleukin-8 (IL-8), inducible nitric oxide synthase (iNOS), prostaglandin E2
(PGE2), and vascular endothelial growth factor (VEGF) levels in gastric juices were measured
by ELISA. The changes of nitrotyrosine in gastric mucosa were measured by immuno-
histochemical staining. The most common dyspeptic symptom in Korean patients with chronic
gastritis was epigastric soreness (76.8%), which was improved significantly after ecabet
sodium treatment (81.7%, p<0.001). Ecabet sodium was more effective in patients with
epigastric pain than vague abdominal discomfort (p = 0.02), especially in patients with old age.
Complete relief of discomfort was more highly achieved in patients with positive Helicobacter
pylori than without (p = 0.01). In spite of clear tendency that the decreased levels of IL-8,
iNOS, and PGE2 and increased levels of VEGF were measured in gastric juices after ecabet
sodium treatment, no statistical significance was noted, which might be due to high inter-
individual variations. The nitrotyrosine expressions were significantly decreased after ecabet
sodium treatment than before (p<0.01). In conclusion, ecabet sodium treatment was very
useful for the relief of dyspeptic symptoms in chronic gastritis, to which both attenuated
inflammatory and enhanced regenerative mechanisms were contributive.
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Introduction
Dyspepsia is one of the most common clinical problems
encountered by either primary physicians or gastroenterology
specialists [1]. It is estimated that about 20–25% of persons
among general population have dyspepsia and the majority
of these persons were classified as functional dyspepsia
after ruling out organic causes [2]. Even though dyspepsia
itself is not a life-threatening condition, patients with
dyspeptic symptoms often interrupt their daily activities
and suffered from poor quality of life. The exact pathogenesis
of dyspepsia is not fully documented, but it has been
suggested to be multi-factorials; for instances, acid-secretory
abnormalities, gastrointestinal motor and sensory dysfunction,
altered visceral perception, psychological factors, and
Helicobacter pylori (H. pylori) infection, etc [3–7].
Since histological evidence of antral gastritis is often
observed in patients with dyspepsia [3, 8, 9], the possibility
that gastric inflammation might contribute to the pathogenesis
of dyspepsia has long been considered, but still remains
under debates [10]. Therefore, there has been no clear
agreement which patients with the endoscopic evidence of
gastritis should be treated or not. The uncertainty of the exact
etio-pathogenic mechanisms of dyspepsia leads to that the
variable methods of treatments attempted with controversial
results in clinical practice [11, 12]. Patients with dyspepsia
usually have been treated with several modalities like acid
suppressants, prokinetic drugs, eradication of H. pylori, and
gastroprotective drugs, but variable treatment outcome has
been reported.
In contrast to western countries, where gastric hyperacidity
might be an important factor for dyspepsia, Asian patients
have somewhat inferior acid secretory capacity compared
with Caucasian patients [13, 14], which can explain why real
prescription in clinic was so much paid to gastroprotective
drugs like prostaglandin derivatives, sucralfate, rebamipide,
ecabet sodium, sofalcon, and teprenone in Asian countries
including Korea and Japan.
Among these several gastroprotectants, ecabet sodium is
derived from pine resin, which has been used for the treatment
of gastric disease from ancient China and showed significant
efficacy in the treatment of gastritis and peptic ulcer disease
[15]. Once administered, ecabet sodium granules topically
enhance gastric mucosal defense, suppress the urease
activity of H. pylori, and show anti-inflammatory activities in
the stomach [16]. Even though several studies documented
that gastroprotective drug frequently prescribed for treatment
of chronic gastritis could diminish gastric inflammation and
enhance the regeneration of damaged mucosa, the report
about the real merits of gastroprotectant on symptom relief
was scarse until now. This study was designed either to
evaluate the clinical efficacy of ecabet sodium on the
treatment of dyspeptic symptoms in patients with chronic
gastritis or to draw the plausible molecular mechanisms to
explain how gastroprotectant like ecabet sodium was effective
in relieving dyspeptic symptoms using the measurements of
changes of mediators in gastric juice, known to reflect the
condition of inflamed gastric mucosa [17–19].
Materials and Methods
Patients
Eight university hospitals in Korea nation-widely
participated in the current prospective clinical trials.
Between February 2002 and January 2003, consecutive
patients who had persistent or recurrent dyspeptic symptoms
such as epigastric pain, soreness, early satiety, fullness,
bloating, nausea, vomiting and belching were recruited to
participate. Persistent symptoms defined that symptoms had
persisted for at least 3 months during last one year. Careful
interview about symptoms like heartburn or substernal pain
was performed by the investigator to exclude patients with
gastroesophageal reflux disease or irritable bowel syndrome.
All patients were underwent upper gastrointestinal endoscopic
examination by gastroenterologists of each institution. Patients
with gastric or duodenal ulcer, reflex esophagitis classified
as higher than LA-A, gastrointestinal malignancy or hiatal
hernia on upper gastrointestinal endoscopy were all
excluded. Patients who had been treated with antacid, H2-
receptor antagonists, proton pump inhibitors and gastro-
protective drugs within 1 week before the study were not
eligible to participate and also patients were not allowed to
take these medications during the study period. Previous
medication history was completely recorded and patients
who had history of gastric or duodenal ulcer, previous
abdominal surgery and with pregnancy were also excluded.
Informed consent was obtained from all patients after detail
explanation. The protocols were also reviewed and approved
in each participating institution under the review of ethical
committee.
Study design
Patient’s medical background, smoking, coffee and alcohol
drinking habit, allergy history, and combined illness were
recorded in detail. Patients with chronic gastritis and erosive
gastritis with upper gastrointestinal endoscopic examination
were enrolled. H. pylori infection was evaluated using rapid
urease test, histology or urea breath test. With two biopsy
samples obtained each from antrum and body, one biopsy
sample each from antrum and body was used for rapid
urease test and histology. H. pylori infection was considered
to be positive if one of the three tests was positive. Blood
was obtained for the laboratory study to exclude organic
diseases. The following variables were determined; leukocyte,
hemoglobin concentration, hematocrit, platelet, total bilirubin,
aspartate aminotransferase, alanine aminotrasferase, alkalineH.Y. Kim et al.
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phosphatase, total protein, albumin, and total cholesterol.
After the enrollment, patients received ecabet sodium 1 g
b.i.d. for 2 weeks. Patient compliance was checked by
counting returned medications at the end of clinical trials
and patients who had taken less than 75% of medications
and had not taken for more than 2 consecutive days were
excluded from the study.
Dyspepsia symptoms were assessed by the investigator with
a questionnaire, consisted of symptoms including epigastric
pain, soreness, early satiety, fullness, bloating, nausea,
vomiting and belching. The symptoms were scored 4-point
Likert scale as follows: 0 (none), no symptoms; 1 (mild),
awareness of symptoms but easily tolerated; 2 (moderate),
symptoms sufficient to cause interference with normal
activities; 3 (severe), incapacitating with an inability to
perform normal activities. After the 2 weeks of treatment,
the investigators assessed the over-all efficacy of treatment.
The degree of improvement was scored 4-point scale as
follows: 0, worsened; 1, no change; 2, slight improvement
(1-point scale improvement); 3, much improvement (2-point
scale improvement). No dyspeptic symptom with ecabet
sodium treatment was classified as complete relief. We
categorized enrolled subjects into 6 groups by age and
symptom improvement was analyzed according to age
groups. Adverse events during treatment were evaluated at
the end of the study and were recorded in the case record
form. An adverse event was defined as any unfavorable or
unintended sign, whether or not considered to be related to
the study drug.
Sixty patients agreed with the collection of specimens
including gastric juices and mucosal biopsies during
endoscopic examination. Twenty milliliters of gastric juices
was aspirated and collected on blue-cap specimen tube with
rapid freezing. These collections of gastric juices were
repeated after the complete of clinical trials. Three pieces of
gastric mucosa were also biopsied and sent to pathology.
Measurement of iNOS, IL-8, PGE2, and VEGF levels of
gastric juices
Proteins were extracted from collected gastric juices
during endoscopic examination and amount of proteins were
measured using BCA methods. Inducible nitric oxide
(iNOS), interleukin-8 (IL-8), prostaglandin E2 (PGE2), and
vascular endothelial growth factor (VEGF) were measured
using ELISA kits (R&D, Mineapolis, MN) according to
manufacturer instruction.
Immunohistochemical staining of nitrotyrosine in biopsied
tissues
Using the 5 µm cut section of paraffinized biopsied sample,
immunohistochemical staining was done using AEC as
chromogen and nitrotyrosine antibody (1:200 dilution, Upstate,
NY) with ABC technology. The intensities of nitrotyrosine
staining were scored according to the degree of intensities
from 0 to 4 (0 = none, 1 = positive staining within one fourth of
observed area (100× magnification), 2 = between one forth and
two fourth, 3 = between half and three fourth, and 4 = more
than three fourth of observed area. Also we considered the
intensities of positive staining with similar criteria.
Statistical analysis
The analyses were made by per protocol approach. The
percentage of patients with symptom improvement and
complete relief according to the individual symptoms were
compared by a paired t test. The percentage of patients with
symptom improvement and complete relief according to the
age groups were compared by a chi-squared test and Fisher’s
exact test. A p value of <0.05 was considered as significant.
Analysis was performed using SAS for Windows version
6.1.
Results
A total of 268 patients were enrolled in this study. Five
patients who took less than 85% of medication were
excluded, leaving 263 patients eligible for analysis. The
demographic characteristics of patients were shown in
Table 1. Endoscopic findings showed chronic superficial
gastritis more than moderate degree and chronic erosive
gastritis in 201 patients and 62 patients, respectively.
The most common symptom was epigastric soreness in
202 (76.8%) patients, followed by epigastric pain (74.1%),
fullness (69.2%), bloating (65.0%), early satiety (60.5%),
belching (39.2%), nausea (38.4%), and vomiting (10.3%)
(Table 2a). Ecabet sodium significantly reduced the score of
all dyspeptic symptoms (p<0.001). Epigastric soreness was
Table 1. Baseline characteristics of the study population
Intent to treat 
(ITT)
Per protocol 
(PP)
Number of patients 268 263
Sex
Male 91 (34.0%) 90 (34.0%)
Female 177 (66.0%) 173 (66.0%)
Age (years, mean ± SD*) 48.8 ± 12.7 48.6 ± 12.6
Liver disease 2 2
Renal disease 1 1
Coffee use 114 111
Smoking 39 39
Alcohol use 71 70
H. pylori status
Positive 58 (52.7%) 56 (53.3%)
Negative 52 (47.3%) 49 (46.7%)
*SD, standard deviationEcabet Sodium for Dyspeptic Symptoms with Molecular Mechanism
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improved most significantly (81.7%) followed by nausea and
epigastric pain. Complete relief of symptom was observed in
59.7% of patients. The percentage of patients free from
vomiting (70.4%) was the highest among symptoms,
followed by nausea and soreness. Belching showed the
lowest symptom resolution.
Patients were largely divided into three groups according
to feature of complained symptom; epigastric pain and
soreness were classified as “pain group” (62 patients) and
other symptoms including early satiety, fullness and bloating
were grouped as “discomfort group” (30 patients). One
hundred and seventy patients had combined symptoms with
pain and discomfort (“combined group”). Treatment outcome
was compared among these groups as shown in Table 2b. In
pain group, 52 out of 62 patients (83.9%) showed symptom
improvement and complete relief was observed in 41 of 62
patients (66.1%). In discomfort group, 19 of 30 patients
(63.3%) and 17 of 30 patients (56.7%) showed symptom
improvement and complete relief, respectively. There was
statistically significant difference in symptom improvement
between pain group and discomfort group (p = 0.02), but
not significant in the achievement of complete relief of
symptoms (p = 0.27). In combined symptom group, there
was significant difference in symptom improvement between
pain and discomfort (p = 0.02) but no difference in complete
relief between these two symptoms (p =0 . 2 7 ) .
Symptom improvement was compared according to age
groups (Table 3a). Higher symptomatic improvements of
epigastric pain and soreness were observed in older age
group of 60–69 years but no statistical significance. On the
other hand, other symptoms except epigastric pain and
soreness improved in high frequency in relatively younger
age groups than older age group, but it was also not
significant. When we did perform the logistic regressional
analysis, discomfort in age group less than 50 showed
statistically significant improvement with ecabet sodium
treatment (p = 0.02) (Table 3b).
Since the association between H. pylori infection and
dyspeptic symptoms had been suggested [3, 7–9], we further
analyzed the changes of symptoms after ecabet sodium
treatment according to H. pylori infection as shown in
Table 4. Although the improvement of pain in combined
group was highly achieved in H. pylori infection group after
ecabet sodium treatment, there was no statistical significance
(p = 0.07). In patients with combined group, complete relief
of discomfort was observed in 20 of 29 patients (69.0%)
with H. pylori infection and in 11 of 30 patients (36.7%)
without infection and there was significant difference
(p =0 . 0 1 ) .
No serious adverse events were reported during the study.
Table 2.  Score of symptoms before and after ecabet sodium treatment
(a) Change of each symptom after treatment with the assessment of treatment outcome
Symptoms (n)
Score (mean ± SD*) Treatment outcome
Treatment Improvement (%) Complete relief (%)
Before After p value
Epigastric pain (195) 1.8 ± 0.6 0.5 ± 0.7 <0.001 154/195 (79.0) 116/195 (59.5)
Soreness (202) 1.7 ± 0.7 0.4 ± 0.7 <0.001 165/202 (81.7) 130/202 (64.4)
Fullness (182) 1.6 ± 0.7 0.6 ± 0.7 <0.001 140/182 (76.9) 102/182 (56.0)
Early satiety (159) 1.6 ± 0.7 0.6 ± 0.7 <0.001 118/159 (74.2) 86/159 (54.1)
Bloating (171) 1.6 ± 0.7 0.6 ± 0.7 <0.001 123/171 (71.9) 93/171 (54.4)
Nausea (101) 1.3 ± 0.6 0.4 ± 0.6 <0.001 81/101 (80.2) 70/101 (69.3)
Vomiting (27) 1.4 ± 0.6 0.4 ± 0.8 <0.001 21/ 27  (77.8) 19/ 27  (70.4)
Belching (103) 1.5 ± 0.7 0.6 ± 0.6 <0.001 74/103 (71.9) 51/103 (49.5)
*SD, standard deviation
(b) Statistical significance of treatment outcome according to symptom group
Symptom (n)
Improvement of symptoms (%) Complete relief of symptoms (%)
N (%) p value N (%) p value
Pain group (62) 52/62 (83.9) 41/62 (66.1)
Discomfort group (30) 19/30 (63.3) 0.02 17/30 (56.7) 0.27
Combined group (170)
Pain dominant 130/170 (76.5) 97/170 (57.1)
Discomfort dominant 111/170 (65.3) 0.02 87/170 (52.1) 0.27H.Y. Kim et al.
J. Clin. Biochem. Nutr.
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Five patients stopped medication due to adverse events such
as epigastric pain, nausea, swollen face and vertigo. The
adverse events were recovered completely and the causal
relationship was described as unlikely by the investigators.
In order to search the underlying mechanisms to explain
the clinical efficacy of ecabet sodium in the treatment of
dyspeptic symptoms of chronic gastritis, we measured the
real levels of IL-8, iNOS, PGE2, and VEGF in gastric juices,
based on the previous investigations [17–19] adopted the
measurements of these mediators to reflect the inflamed and
regenerating status of gastric mucosa (Fig. 1a). The mean
levels of IL-8, iNOS and VEGF were 27.19 ± 4.15, 5.68 ±
0.43, and 45.08 ± 35.91 ng/ml before ecabet sodium treatment
and 24.19 ± 4.22, 4.91 ± 0.60, and 43.39 ± 23.55 ng/ml after
ecabet sodium treatment, respectively. Although there was
tendency that IL-8 and iNOS was decreased much more
after ecabet sodium treatment and VEGF increased after
treatment, but none was statistically significant. The PGE2 level
Table 3.  Number of patients with improvement of symptoms according to age groups
(a) Statistical significance with the changes of symptom according to age group after treatment
Symptom
Age group (N, %)
p value
20–29 30–39 40–49 50–59 60–69 70–
Epigastric pain 12/15 21/27 47/60 38/49 33/39 3/5 0.82
(80.0) (77.8) (78.3) (77.6) (84.6) (60.0)
Soreness 13/16 25/31 49/62 40/48 35/41 3/4 0.94
(81.3) (80.7) (79.3) (83.3) (85.4) (75.0)
Fullness 14/18 24/28 45/56 28/39 26/35 3/6 0.43
(77.8) (85.7) (80.4) (71.8) (74.3) (50.0)
Early satiety 14/17 18/25 35/44 25/33 25/35 1/5 0.15
(82.4) (72.0) (79.6) (75.8) (71.4) (20.0)
Bloating 14/16 19/25 39/51 26/38 23/35 2/6 0.17
(87.5) (76.0) (76.5) (68.4) (65.7) (33.3)
Nausea 12/14 14/17 22/29 15/18 15/19 3/4 0.98
(85.7) (82.4) (75.9) (83.3) (79.0) (75.0)
Vomiting 1/2 5/6 6/8 6/6 2/3 1/2 0.44
(50.0) (83.3) (75.0) (100) (66.7) (50.0)
Belching 11/13 12/15 19/25 15/24 15/22 2/4 0.56
(84.6) (80.0) (76.0) (62.5) (68.2) (50.0)
(b) Multiple regression analysis of the changes of symptom according to age group after treatment
Symptom
Age group (N, %)
20–29 30–39 40–49 50–59 60–69 70–
Pain group 14/18 (77.9) 26/34 (76.5) 54/70 (77.1) 47/59 (79.7) 37/45 (82.2) 4/6 (66.7)
Multiple regression p value 0.93
Discomfort group 14/18 (77.9) 19/28 (67.9) 45/61 (73.8) 30/46 (65.2) 21/41 (51.2) 1/6 (16.7)
Multiple regression p value 0.02
Table 4.  Improvement and complete relief of symptom in pain and discomfort group according to H. pylori infection
Symptom (n)
Improvement (N, %) Complete relief (N, %)
HP (+) HP(−) p value HP (+) HP (−) p value
Pain group (42) 22/26 (84.6) 13/16 (81.2) 1.0 14/26 (53.8) 10/16 (62.5) 0.58
Combined group (59)
Pain (59) 25/29 (86.2) 20/30 (66.7) 0.07 18/29 (62.1) 13/30 (43.3) 0.07
Discomfort (59) 24/29 (82.8) 21/30 (70.0) 0.24 20/29 (69.0) 11/30 (36.7) 0.01
Discomfort group (4) 1/1   (100) 3/3   (100) 0 1/1   (100) 2/3   (66.7) 0Ecabet Sodium for Dyspeptic Symptoms with Molecular Mechanism
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before ecabet sodium treatment was 704.25 ± 436.69 ng/ml,
which was decreased to 149.51 ± 41.1 ng/ml, but also no
statistical significance (p = 0.24). The reason of this statistical
insignificance of these mediators by ELISA measures might
be too diverse individual variations of each mediator in spite
of tendency of changes. The changes of nitrotyrosine
expressions, the index of oxidative stress in gastritis [20],
were significantly decreased after the treatment of ecabet
sodium (Fig. 2a & 2b). The levels of nitrotyrosine expression
were markedly decreased after the treatment of ecabet
sodium (Fig. 2a). There was statistical significance in the
levels of nitrotyrosine between before and after ecabet
sodium treatment (p<0.01, Fig. 2b).
Discussion
The current study revealed that the gastroprotective drug,
ecabet sodium, was very effective in the treatment of
dyspepsia symptom originated from chronic gastritis based
on the considerable rates of symptom relief, no serious
side effects, and high compliance. Moreover, the significant
changes in either decreasing cytokines or mediators responsible
for perpetuating inflammation or increasing mediators involved
in regeneration were observed in gastric juices after ecabet
sodium administration, which could explain the mechanisms
of clinical improvement in the treatment of dyspepsia of
chronic gastritis [29].
Although there have been several studies showing that
cytoprotective drug revealed several advantages of anti-
inflammation, antioxidation, accelerating ulcer healing, and
the achievement of quality of healing [21, 22], there were
few trials that had addressed the real clinical benefit of
symptom resolution in patients with chronic gastritis in
addition to attenuated inflammatory activities. The reason
for this rarity of reports was due to the absence of the any
objective measures available for assessing treatment success
of gastric cytoprotective drug [23]. In the current study, even
though we could document the clear tendency of the changes
of inflammatory mediators or cytokines in gastric juices, the
statistical significance was not seen due to rather high
individual variations of their levels.
Also there was clear difference in life style and perception
of dyspeptic symptoms between Western and Orient. For
example, Talley N.J. et al. [24] published one report done
with rebamipide that the gastroprotective drug did not show
any benefit in the treatment of functional dyspepsia, but
which might be due to the inappropriateness of parameter
adopted. In addition, a high placebo response has been a
matter of concern in previous trials using less stringent
endpoints than complete relief of symptoms parameter used
in this study [23, 25]. Since the aim of our study was to
document the in detail changes of dyspeptic symptoms after
ecabet sodium, we did not consider the comparison study
including placebo. However, as referenced with placebo
response rate like our study, the current study showed
symptom improvement in more than 70% of studied subjects
Fig. 1. The changes of iNOS, IL-8, PGE2, and VEGF amounts in gastric juice after ecabet sodium treatment. ELISA measurements of
gastric juices were repeated before and after ecabet sodium according to manufacturer’s suggestions.H.Y. Kim et al.
J. Clin. Biochem. Nutr.
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that was higher than placebo response in other studies.
Moreover, in the current our trial, we prospectively evaluated
the changes of dyspeptic symptoms in detail and classified
the symptoms into largely three main groups. All these
evaluations were scored objectively by clinical coordinators,
who instruct the patient score properly and performed in
several institutions with the same protocol guideline. Also
we performed the biologic evaluation to support the clinical
outcomes.
Although close association between dyspepsia and H.
pylori infection has been suggested [3, 7–9], it still remains
not completely documented. In our study, there was no
relation between the presence of H. pylori and the incidence
of dyspepsia in patients with chronic gastritis. Therefore,
ecabet sodium was not more effective in patients with H.
pylori-associated chronic gastritis. Our prospective study was
designed to investigate whether cytoprotective therapy with
ecabet sodium 1 g b.i.d. would provide the real advantage of
symptom relief in dyspeptic patients with chronic gastritis.
As a result, soreness was the most common symptom and
the best responded to ecabet sodium treatment followed by
nausea and epigastric pain. Discomfort is a term used to
describe a subjective, negative feeling that patient does not
interpret as pain, which can include upper abdominal fullness,
early satiety, bloating. There was significant difference in
symptom improvement between pain group and discomfort
group after ecabet sodium treatment and also in combined
symptom group with pain and discomfort, the significant
difference in symptom improvement was observed. As 2
weeks treatment duration might be short to obtain the best
effective therapeutic benefit, longer duration of treatment
may have more benefits.
If gastric cytoprotective drugs are efficacious for symptom
resolution in patients with chronic gastritis, by what
mechanisms do they improve symptoms? The possible
explanation may relate to the mucosa being more sensitive
in dyspeptic patients with chronic gastritis. The several
studies [8,  26,  27,  29] showed that gastric inflammatory
reaction is basically related to dyspeptic symptoms. Although
controversial, it was reported that H. pylori infection was
associated with significant gastric sensitivity to dyspeptic
symptoms [26]. As the causal association between H. pylori
infection and gastritis is well established, gastric mucosal
inflammation may play a key role in enhancing gastric
sensitivity to dyspeptic symptoms. Although we hypothesized
that ecabet sodium might show better efficacy in H. pylori
infected patients, there was no significant difference in
symptom improvement between H. pylori positive and
negative patients except combined symptom group with pain
and discomfort. We inferred that the small number of
patients with H. pylori infection might make this discrepancy.
Therefore, further large scaled studies are necessary to
document this suggestion.
In the current study, we compared the real levels of
Fig. 2. The change of nitrotyrosine expressions after ecabet sodium treatment. (a) The immunohistochemical expressions of
nitrotyrosine (×100 magnification). The expressions of nitrotyrosine were observed in epithelium, submucosal tissues, but its
expressions were markedly decreased after ecabet sodium treatment. (b) The changes of mean expression of nitrotyrosine
before and after ecabet sodium treatment.Ecabet Sodium for Dyspeptic Symptoms with Molecular Mechanism
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inflammatory mediators such as IL-8, iNOS, PGE2 in gastric
juices and nitrotyrosine in gastric mucosa which levels were
decreased after ecabet sodium treatment whereas VEGF, one
of key growth factors essential in mucosal regeneration,
were apparently increased after ecabet sodium treatment.
Although we could not find statistically significant decrease
in IL-8, iNOS, PGE2 as seen in Fig. 1, this could be
explained by the wide variation of the individual levels in
spite of clear decreasing tendency. Even though we tried to
check the changes of inflammation scores before and after
ecabet sodium, non-consistency in scoring among the
pathologists of participating institutions and sites of biopsied
tissues moved to compare the intensities of nitrotyrosin
immunostaining and the levels of some mediators in aspirated
gastric juices in the current trial.
Recently it was reported that ecabet sodium might improve
symptoms in patients with dysmotility-like dyspepsia by
gastric adaptive relaxation in animal model [28] and
showed similar clinical efficacy with cimetidine on functional
dyspepsia [29]. Epigastric pain and soreness improved
markedly than other symptoms and belching showed the
lowest symptom resolution in both improvement and complete
relief analysis in this study. This result suggested that symptom
improvement with ecabet sodium treatment could be obtained
by mainly gastric cytoprotective mechanisms along with by
the improvement of decreased reservoir function of stomach.
However, further in vivo experiments are necessary to
confirm this hypothesis.
The current study also suggested that ecabet sodium
treatment was well tolerated and safe because no significant
adverse effects were noted during the study period. Although
five patients stopped the medication, it was finally proved to
be not associated with medications.
In conclusion, ecabet sodium was useful in the management
of dyspeptic symptoms with chronic gastritis irrespective of
H. pylori infection in Korea. Epigastric soreness and pain
were the best-responded symptoms with ecabet sodium
treatment. Even though gastric cytoprotective mechanisms
including anti-inflammation, antioxidation, and enhanced
regeneration could attribute to the mechanisms to explain
the attenuation of dyspeptic symptoms, further investigation
about its long-term benefit and more detailed evaluation
with larger scales are warranted.
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